SAFETY DATA SHEET



1. Identification

Product identifier IMURAN TABLETS

Other means of identification

Synonyms IMURAN 25 MG TABLETS * IMURAN 50 MG TABLETS * IMUREK FILMTABLETTEN * IMUREL

TABLETS * AZATHIOPRINE, FORMULATED PRODUCT

Recommended use Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Recommended restrictions No other uses are advised.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US

5 Moore Drive

Research Triangle Park, NC 27709 USA

US General Information (normal business hours): +1-888-825-5249

Email Address: msds@gsk.com Website: www.gsk.com EMERGENCY PHONE NUMBERS -TRANSPORT EMERGENCIES::

US / International toll call +1 703 527 3887

available 24 hrs/7 days; multi-language response

2. Hazard(s) identification

Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
AZATHIOPRINE	BW 57322 * CCI 3738 * 6-(1-METHYL-4-NITROIMIDAZOL-5-YL-THI O)PURINE * 6-(1-METHYL-4-NITRO-5-IMIDAZOLYL)ME RCAPTOPURINE * 1565 (GW ACN)	446-86-6	31.4 - < 31.8
STARCH	ARROWROOT STARCH * CORN STARCH * POTATO STARCH * RICE STARCH	9005-25-8	10 - < 20
HYDROXYPROPYL METHYL CELLULOSE	METHOCEL K4M * GONIOSOL * ISOPRO ALKALINE * METHOCEL E,F,K * METHOCEL HG * METHYL CELLULOSE PROPYLENE GLYCOL ETHER * HYPROMELLOSE * CELLULOSE, 2-HYDROXYPROPYL METHYL ESTER * METHYLHYDROXYPROPYLCELLULOSE * PHARMACOAT 603	9004-65-3	1-<3

Material name: IMURAN TABLETS SDS US

123443 Version #: 13 Revision date: 11-06-2014 Issue date: 11-06-2014

Chemical name	Common name and synonyms	CAS number	%
MAGNESIUM STEARATE	STEARIC ACID, MAGNESIUM SALT * MAGNESIUM DISTEARATE * DIBASIC MAGNESIUM STEARATE * MAGNESIUM DISTEARATE, PURE	557-04-0	<1
TITANIUM DIOXIDE	TITANIUM OXIDE * TITANIUM(IV) OXIDE * TITANIUM PEROXIDE (TiO2) * PIGMENT WHITE 6	13463-67-7	< 0.2
0.1			

Other components below reportable levels

40 - < 50

4. First-aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eve contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control center immediately. Do not induce vomiting without

advice from poison control center.

Most important symptoms/effects, acute and

delayed

Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), nausea, vomiting, increased susceptibility to infection.

Indication of immediate medical attention and special

treatment needed

General information

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center.

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

None known.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Fire fighting

equipment/instructions

Move containers from fire area if you can do so without risk.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions. protective equipment and emergency procedures

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.

Environmental precautions Avoid discharge into drains, water courses or onto the ground.

Material name: IMURAN TABLETS SDS US

^{*}Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

7. Handling and storage

Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

GSK Components	Туре	Value	Note
AZATHIOPRINE (CAS 446-86-6)	8 HR TWA	3 mcg/m3	
110 00 0)	OHC	4	CARCINOGEN
		4	REPRODUCTIVE HAZARD
		4	SKIN SENSITISER
HYDROXYPROPYL METHYL CELLULOSE (CAS 9004-65-3)	OHC	1	
US. OSHA Table Z-1 Limits	for Air Contaminants (29 CFR 1910.1000))	
Components	Туре	Value	Form
STARCH (CAS 9005-25-8)	PEL	5 mg/m3	Respirable fraction.
·		15 mg/m3	Total dust.
TITANIUM DIOXIDE (CAS 13463-67-7)	PEL	15 mg/m3	Total dust.
US. ACGIH Threshold Limi	t Values		
Components	Туре	Value	
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	
STARCH (CAS 9005-25-8)	TWA	10 mg/m3	
TITANIUM DIOXIDE (CAS 13463-67-7)	TWA	10 mg/m3	
US. NIOSH: Pocket Guide t	to Chemical Hazards		
Components	Туре	Value	Form
STARCH (CAS 9005-25-8)	TWA	5 mg/m3 10 mg/m3	Respirable. Total
logical limit values	No biological exposure limits noted for th	ne ingredient(s).	
oosure guidelines		3 (,	
propriate engineering atrols	General ventilation normally adequate. A operations involving this material based outcome of a site- or operation-specific r	upon the OEL/Occupationa	
ividual protection measures	s, such as personal protective equipment	:	
Eye/face protection	If contact is likely, safety glasses with sic	de shields are recommende	ed.
Skin protection			
Hand protection	land protection For prolonged or repeated skin contact use suitable protective gloves.		
Other			
Respiratory protection	Use a NIOSH/MSHA approved respirator if there is a risk of exposure to dust/fume at levels exceeding the exposure limits. No personal respiratory protective equipment normally required.		
Thermal hazards	Wear appropriate thermal protective clot		ar is ment mention, regulation
	1123. appropriate troiling protocity office		

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

Material name: IMURAN TABLETS

General hygiene

considerations

SDS US

123443 Version #: 13 Revision date: 11-06-2014 Issue date: 11-06-2014

9. Physical and chemical properties

Appearance

Physical state Solid.
Form Tablet.

Color Not available.

Odor Not available.

Odor threshold Not available.

PH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density

Not available.

Relative density

Not available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoidContact with incompatible materials.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

None known. Irritating and/or toxic fumes and gases may be emitted upon the product's

decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Health injuries are not known or expected under normal use. **Eye contact** Health injuries are not known or expected under normal use.

Ingestion Health injuries are not known or expected under normal use. May be harmful if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics Accidental exposure or contact might produce: nausea, vomiting, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), increased susceptibility to infection.

Information on toxicological effects

Expected to be a low hazard for usual industrial or commercial handling by trained personnel. May

be harmful if swallowed.

Components	Species	Test Results
AZATHIOPRINE (CAS 446-8	36-6)	
Acute		
Oral		
LD50	Rat	400 mg/kg
HYDROXYPROPYL METHY	L CELLULOSE (CAS 9004-65-3)	
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)	
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
TITANIUM DIOXIDE (CAS 1	3463-67-7)	
Acute		
Inhalation		
LC50	Rat	6820 mcg/m3
Oral		
LD50	Rat	> 24 g/kg
Chronic		
Inhalation		
LOEC	Rat	8.6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years Highest dose
		5 mg/m3, 24 months
Subacute		
Inhalation		
LOEL	Rat	0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract.
Oral		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.
Subchronic		
Inhalation		
LOEC	Rat	3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

^{*} Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin TITANIUM DIOXIDE

0, Literature data Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human

Material name: IMURAN TABLETS SDS US

Irritation Corrosion - Skin

TITANIUM DIOXIDE Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE 0

Serious eye damage/eye Health injuries are not known or expected under normal use.

irritation

Eye

TITANIUM DIOXIDE OECD 405, Literature data

Result: Mild irritant Species: Rabbit

Species: Rabi

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory or skin sensitization

Respiratory sensitization No studies have been conducted. **Skin sensitization** May cause an allergic skin reaction.

Maximisation assay (Magnusson and Kligman)

HYDROXYPROPYL METHYL CELLULOSE Result: Negative

Species: Guinea pig

Sensitization

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: Negative Species: Guinea pig

Test Duration: 48 hour exposure

AZATHIOPRINE Occupational exposure, Literature data

Result: Low incidence of contact hypersensitivity.

Species: Human

TITANIUM DIOXIDE Patch test, Literature data

Result: Negative Species: Human

Germ cell mutagenicity May cause genetic defects.

Mutagenicity

TITANIUM DIOXIDE

AZATHIOPRINE Ames Assay, GLP assay; Literature data

Result: Positive Ames, Literature data Result: Negative

Micronucleus Assay in vitro, CHO cells, Literature data

Result: Negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: Positive

AZATHIOPRINE Micronucleus Test, GLP assay; Literature data

Result: Positive

TITANIUM DIOXIDE Syrian Hamster Embryo (SHE) cell transformation assay

Result: Negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: Positive

Carcinogenicity
TITANIUM DIOXIDE

Contains a material (Azathioprine) classified as a carcinogen by external agencies.

0.5 mg/m3, Literature data

Result: Negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: Negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

Material name: IMURAN TABLETS

Carcinogenicity

TITANIUM DIOXIDE 25000 - 50000 ppm, Dietary study

Result: Negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: Negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

AZATHIOPRINE Literature search Result: Positive

IARC Monographs. Overall Evaluation of Carcinogenicity

AZATHIOPRINE (CAS 446-86-6) 1 Carcinogenic to humans.

TITANIUM DIOXIDE (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

US. National Toxicology Program (NTP) Report on Carcinogens

AZATHIOPRINE (CAS 446-86-6) Known To Be Human Carcinogen.

May damage fertility or the unborn child. Reproductive toxicity

Reproductivity

AZATHIOPRINE Literature search

Result: Positive for teratogenicity, fertiltiy effects and may

affect the quality of breast milk.

Specific target organ toxicity -

single exposure

Not available.

Specific target organ toxicity -

repeated exposure **AZATHIOPRINE** Causes damage to organs through prolonged or repeated exposure.

Literature search

Organ: Immune system, Bone marrow and formation of blood

cells, Liver, Kidney

Not likely, due to the form of the product. **Aspiration hazard**

Prolonged inhalation may be harmful. Prolonged exposure may cause chronic effects. Causes **Chronic effects**

damage to organs through prolonged or repeated exposure.

Further information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test Results
AZATHIOPRINE (CAS	S 446-86-6)		
Acute			
	IC50	Activated sludge	> 1000 mg/l, 3 hours
Aquatic			
Acute			
Algae	EC50	Green algae (Scenedesmus subspicatus)	> 100 mg/l, 72 hours Static test
	NOEC	Green algae (Scenedesmus subspicatus)	100 mg/l, 72 hours Static test
Crustacea	EC50	Water flea (Daphnia magna)	> 100 mg/l, 48 hours Static test
	NOEC	Water flea (Daphnia magna)	> 100 mg/l, 48 hours Static test
HYDROXYPROPYL N	METHYL CELLULO	SE (CAS 9004-65-3)	
Aquatic			
Acute			
Fish	EC50	Fish	> 100 mg/L, 96 hours

123443 Version #: 13 Revision date: 11-06-2014 Issue date: 11-06-2014

Components Species Test Results

MAGNESIUM STEARATE (CAS 557-04-0)

Aquatic

Acute

Fish EC50 Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours

latipes)

TITANIUM DIOXIDE (CAS 13463-67-7)

Aquatic Acute

Crustacea EC50 Water flea (Daphnia magna) > 1000 mg/l, 48 hours Static test

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

AZATHIOPRINE 4 %, 28 days Modified Zahn-Wellens, DOC removal.,

Activated sludge

4 %, 28 days Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge

MAGNESIUM STEARATE 77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

AZATHIOPRINE -0.787 HYDROXYPROPYL METHYL CELLULOSE -5

Bioconcentration factor (BCF)

HYDROXYPROPYL METHYL CELLULOSE 3.2 Estimated MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general

Volatility

Henry's law

AZATHIOPRINE 0 atm m^3/mol, 25 C Estimated

HYDROXYPROPYL METHYL CELLULOSE 0 atm m3/mol Estimated

Other adverse effects Not available.

13. Disposal considerations

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste codeThe waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

^{*} Estimates for product may be based on additional component data not shown.

14. Transport information

DOT

Not regulated as a dangerous good.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

the IBC Code

15. Regulatory information

US federal regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

No

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

Z Mazaruous

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. California Controlled Substances. CA Department of Justice (California Health and Safety Code Section 11100)

Not listed.

US. Massachusetts RTK - Substance List

AZATHIOPRINE (CAS 446-86-6)

STARCH (CAS 9005-25-8)

TITANIUM DIOXIDE (CAS 13463-67-7)

US. New Jersey Worker and Community Right-to-Know Act

TITANIUM DIOXIDE (CAS 13463-67-7)

US. Pennsylvania Worker and Community Right-to-Know Law

AZATHIOPRINE (CAS 446-86-6) STARCH (CAS 9005-25-8)

TITANIUM DIOXIDE (CAS 13463-67-7)

US. Rhode Island RTK

Not regulated.

Material name: IMURAN TABLETS SDS US

US. California Proposition 65

WARNING: This product contains a chemical known to the State of California to cause cancer and birth defects or other reproductive harm.

US - California Proposition 65 - CRT: Listed date/Carcinogenic substance

AZATHIOPRINE (CAS 446-86-6) Listed: February 27, 1987 TITANIUM DIOXIDE (CAS 13463-67-7) Listed: September 2, 2011

US - California Proposition 65 - CRT: Listed date/Developmental toxin

AZATHIOPRINE (CAS 446-86-6) Listed: September 1, 1996

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	Yes
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	Yes
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

 Issue date
 11-06-2014

 Revision date
 11-06-2014

Version # 13

Further information HMIS® is a registered trade and service mark of the NPCA.

HMIS® ratings Health: 2*

Flammability: 0 Physical hazard: 0

NFPA ratings Health: 2

Flammability: 0 Instability: 0

References GSK Hazard Determination

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Revision Information Product and Company Identification: Business Units

Composition / Information on Ingredients: Ingredients

Exposure Controls / Personal Protection:

Physical & Chemical Properties: Ecological Information: Ecotoxicity

Transport Information: Agency Name, Packaging Type, and Transport Mode Selection

Regulatory Information: Risk Phrases - Class.

GHS: Classification

Material name: IMURAN TABLETS SDS US